Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment
By Sabela Ojea
Phathom Pharmaceuticals said the U.S. Food and Drug Administration approved Voquezna to treat a type of esophagus inflammation.
The commercial-stage biopharmaceutical company said the FDA approved the novel potassium-competitive acid blocker as a new treatment for adults dealing with erosive esophagitis.
The approval is based on positive results from the phase 3 Phalcon-EE study, which enrolled over 1,000 patients in the U.S. and Europe.
Voqezna is expected to be available in the U.S. in December, the company said.
The FDA approval entitles Phathom Pharmaceuticals to receive a $175 million payment, which will fund the commercial launch.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 01, 2023 17:35 ET (21:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying